iifl-logo-icon 1

Vardhaman Laboratories Ltd Share Price

0.51
(4.08%)
Aug 16, 2019|02:10:39 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Vardhaman Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

0.51

Prev. Close

0.49

Turnover(Lac.)

0

Day's High

0.51

Day's Low

0.51

52 Week's High

0

52 Week's Low

0

Book Value

4.82

Face Value

10

Mkt Cap (₹ Cr.)

0.21

P/E

0

EPS

0

Divi. Yield

0

Vardhaman Laboratories Ltd Corporate Action

No Record Found

Vardhaman Laboratories Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Vardhaman Laboratories Ltd SHAREHOLDING SNAPSHOT

24 Aug, 2024|09:40 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 37.19%

Foreign: 0.00%

Indian: 37.19%

Non-Promoter- 0.11%

Institutions: 0.10%

Non-Institutions: 62.69%

Custodian: 0.00%

Share Price

Vardhaman Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2018Mar-2017Mar-2016Mar-2015

Equity Capital

4.12

4.12

4.12

4.12

Preference Capital

0

0

0

0

Reserves

-2.13

-2.09

-2.05

-2.02

Net Worth

1.99

2.03

2.07

2.1

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2018Mar-2017Mar-2016Mar-2015

Revenue

0

0

0

0

yoy growth (%)

0

0

0

0

Raw materials

0

0

0

0

As % of sales

0

0

0

0

Employee costs

0

0

0

0

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2018Mar-2017Mar-2016Mar-2015

Profit before tax

-0.04

-0.03

-0.03

-0.02

Depreciation

0

0

0

0

Tax paid

0

0

0

0

Working capital

-0.04

-0.04

-0.02

-0.02

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2018Mar-2017Mar-2016Mar-2015

Growth matrix (%)

Revenue growth

0

0

0

0

Op profit growth

1.71

-6.03

43.03

42.69

EBIT growth

7.75

18.33

20.38

19.33

Net profit growth

7.75

18.33

20.38

19.33

View Ratios

No Record Found

Vardhaman Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,776.15

150.914,20,027.58237.820.774,409.7498.75

Divis Laboratories Ltd

DIVISLAB

4,855.95

78.491,30,370.294300.612,063507.93

Cipla Ltd

CIPLA

1,575

32.241,28,058.811,055.940.823,752.25346.4

Zydus Lifesciences Ltd

ZYDUSLIFE

1,178.65

27.871,21,729.161,700.80.254,035.4156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,953.2

28.241,16,346.951,417.20.575,823.91,458.7

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Vardhaman Laboratories Ltd

Management

Register Office

Registrar Office

Chairman

Dharamchand Shah

Director

Sunil D Shah

Director

Sumedh Shah

Director

Dayanand Naik

Director

Umesh Patil

Director

Rajendra Petare

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Vardhaman Laboratories Ltd was incorporated on 24th April, 1985 under the Companies Act, 1956, in the State of Maharashtra as Vardhaman Laboratories Private Limited ans subsequently converted into a Public Limited vide Special Resolution dated 15th October, 1993 and obtained a fresh Certificate of Incorporation to change of name on 7th December, 1993 as Vardhaman Laboratories Limited, from the Registrar of Companies Maharashtra, Bombay, Consequent on the conversion of the company from Pvt. Ltd to Public Ltd.At present the Company is engaged in manufacturing varieties of formulations and marketing under the brand name of Samrat gained sizable popularity in the area of Western Maharashtra and Southern part of India.The Company started its operation on a small scale basis and during this time was also in the process of identifying a viable project in the pharmaceutical industry. After a thorough and exhastive study, the project for manufacturing the Bulk Drugs as mentioned aboves was conceived in December 1993.During 1998-99, the company has added new formulation products like Ciprofloxin, Norfioxaoin, Ranitidine, etc. It has also obtained export orders for Cotrimethaxile tablets & Paracetemol Caffeine tablets which has been completed.
Read More

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp